TD Cowen started coverage on shares of Anteris Technologies Global (NASDAQ:AVR – Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $15.00 target price on the stock.
A number of other equities analysts also recently weighed in on AVR. Cantor Fitzgerald began coverage on shares of Anteris Technologies Global in a research note on Tuesday. They set an “overweight” rating and a $9.00 target price for the company. Barclays began coverage on shares of Anteris Technologies Global in a research note on Tuesday. They set an “overweight” rating and a $22.00 target price for the company.
Check Out Our Latest Stock Analysis on Anteris Technologies Global
Anteris Technologies Global Trading Down 2.1 %
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Featured Articles
- Five stocks we like better than Anteris Technologies Global
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 3 Fintech Stocks With Good 2021 Prospects
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- 3 Monster Growth Stocks to Buy Now
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
